Business Context and Reporting Period
Company: Incyte Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: Incyte is a drug discovery and development company focused on proprietary small molecule drugs for oncology and inflammation. The company transitioned from an information products business to a pure-play biopharmaceutical entity in 2004. As of year-end 2009, the company had no approved products and generated revenue solely through licensing and collaboration agreements.
Key Financial Metrics
| Metric | 2009 | 2008 |
|---|---|---|
| Total Revenues | $9.3 million | $3.9 million |
| Net Loss | $(211.9) million | $(178.9) million |
| Loss Per Share (Basic & Diluted) | $(2.06) | $(1.99) |
| Research & Development Expenses | $119.4 million | $146.4 million |
| Cash, Cash Equivalents & Marketable Securities | $473.9 million | $217.8 million |
| Working Capital | $523.2 million | $155.2 million |
| Total Debt (Principal Amount) | $594.6 million | $594.6 million |
| Stockholders' Deficit | $(102.4) million | $(220.8) million |
Note: The company reported a significant non-cash loss of $34.3 million related to the mark-to-market adjustment of an embedded derivative liability on convertible senior notes.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 136% to $9.3 million, driven primarily by the recognition of upfront fees from new collaboration agreements with Novartis and Eli Lilly. Contract revenues rose from $0.7 million in 2008 to $5.8 million in 2009.
- Net Loss Expansion: Net loss increased by $33.0 million (18%) to $211.9 million. This was largely due to a $34.3 million non-cash charge for the embedded derivative liability and increased interest expense ($32.1 million vs. $24.9 million), partially offset by a decrease in R&D expenses.
- Liquidity Improvement: Cash and marketable securities more than doubled to $473.9 million, resulting from a $132.3 million public equity offering and $387.4 million in proceeds from new convertible senior notes, net of debt repurchases.
- Debt Restructuring: The company repurchased $227.2 million in aggregate principal amount of older convertible notes during 2009, resulting in a $5.7 million loss on repurchase.
Guidance, Outlook, and Risks
Strategic Developments
- Novartis Collaboration: Entered in November 2009. Novartis received exclusive rights outside the U.S. for INCB18424 (JAK inhibitor) and worldwide rights for INCB28060 (c-MET inhibitor). Incyte received a $150 million upfront payment and a $60 million milestone payment (recognized in 2010).
- Lilly Collaboration: Entered in December 2009. Lilly received worldwide rights for INCB28050 (JAK inhibitor for inflammation). Incyte received a $90 million upfront payment.
- Clinical Pipeline: INCB18424 is in Phase III for myelofibrosis (U.S. and Europe). INCB28050 is in Phase II for rheumatoid arthritis. INCB7839 (Sheddase inhibitor) showed positive Phase II results in breast cancer.
Outlook and Risks
- Profitability: Management expects to continue incurring losses for several years as it expands drug discovery and development programs. No product sales are expected for several years.
- Liquidity Needs: While current cash resources are deemed adequate for at least 12 months, the company anticipates needing additional capital to fund operations and repay indebtedness. Future financing may be dilutive or restrictive.
- Debt Obligations: The company has substantial leverage ($594.6 million principal). The indenture for the 4.75% convertible senior notes limits the ability to incur additional indebtedness or create liens.
- Regulatory Risk: Success depends on obtaining FDA approval for drug candidates. Clinical trials are lengthy, expensive, and uncertain. A Special Protocol Assessment (SPA) was obtained for the myelofibrosis trial, but this does not guarantee approval.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $473.9 million cash balance against projected R&D burn rates and debt service obligations (approx. $19 million annual interest on 4.75% notes).
- Revenue Recognition: Confirm the amortization schedule for the $240 million in deferred revenue from Novartis and Lilly upfront payments, which will be recognized over several years (2010–2016).
- Debt Covenants: Review the restrictive covenants in the 4.75% convertible senior notes indenture regarding additional indebtedness and asset dispositions.
- Clinical Milestones: Monitor the enrollment and results of the Phase III myelofibrosis trial for INCB18424, as this is the primary catalyst for future product revenue.
- Derivative Accounting: Understand the impact of the $34.3 million non-cash derivative loss and the subsequent reclassification of the embedded conversion feature to equity.